Mike, you, Thank good afternoon, and everyone.
one The third a quarter was DURECT. strong for
for in continued The results fronts. We the study meeting. DUR-XXX We and were Association the program selected The and trial all inclusion IIa, Disease endpoints, announced Liver MELD scores. bilirubin, flagship Phase slide presentation Of Liver important the Meeting Study Best alcoholic deck our for to advance for data impressive Lille on for DUR-XXX and on AASLD summary hepatitis an including or late-breaking oral American the of XXXX completed
trial opposed In a Phase trial control addition, of with has analysis to historic enrollment results for trial announced been that We meeting comparative for and the our committee XXXX. accepted as the DUR-XXX completion Phase FDA an and halfway psoriasis January IIb DUR-XXX of presentation. the a of NASH file The trial XX, -- agreed to NDA point scheduled an submission as passed the POSIMIR had enrollment. NDA Ib in advisory
signed investigational we HIV product. development injectable addition, a of In long-acting deal for and with Gilead commercialization a the
received to go milestone the upfront during earned $XX we also We and the payment received payment quarter. million the first million that $XX along with
inflammatory such cell chronic atopic homeostasis, is such important NASH dermatitis. survival regulator may kidney functions as and program in and an plays have occurring, and applicability broad DURECT's and skin acute tissue It and liver hepatitis injuries, small of DUR-XXX. molecule primary acute lead naturally focus, role in organ though, such alcoholic remains inflammation, as a and regeneration. disorders, as diseases, psoriasis injuries DUR-XXX the first-in-class on lipid molecule, the our epigenetic regulatory vital that
for alcoholic and DUR-XXX non-alcoholic psoriasis hepatitis developing by topical steatohepatitis oral indications: by administration. X are dosing, by or or We AH NASH injection, initial
our with program. begin hepatitis alcoholic I'll
with States. the Phase X significant and up with determined in doses mortality of AH alcoholic clinical the that to multicenter for MELD patients we dose-escalation was DUR-XXX pharmacokinetics the by study, quarter, with intravenously the IIa doses study, This patients United a In were administered no unmet of -- represents During can as open-label, The moderate severe of completed with severe medical need AH in therapies. XX%. be rate for this their hepatitis near-term conducted study X XX- XX-, a treated moderate or evaluating DUR-XXX. was approved and AH safety initial score. and XXX-milligram and
X End-Stage scoring prognosis of and patients scores or for patients liver staging assess MELD from of total between XX, is the to for groups objectives assessment pharmacodynamic by of system announced and for Disease we biomarkers and liver of patients. the AH developed XX Liver with XX, is moderate used positive MELD trial September score and chemistry, final between Model and consisted to virtue trial of severity XX AH each Study a these The had score severe dose Lille safety, of completion of treatment, of X The enrollment model. XX patients. included XX the the data. transplantation response a scores pharmacokinetics and XX, signals and MELD that for and On including had prognostic also that of the a or patients
historic historic was Patients or and this patient baseline in We patient study and the Day of -- used in disease. no prognosis comparison. on -- survival treated MELD the statistically -- historic better with in the historic bilirubin patients baseline levels of and evaluation Lille statistically used as X control scores with AH statistically similar control reduction are Day DUR-XXX to reductions scores -- clinical University a in levels and probability significant days of significant a This lower significant -- study responses determine Lille serum scores of on Day that help on prognosis X of the treatment. patient XX this severity And consisted after there for was that XX. XX. Day to MELD a or X score, have Day patients from Louisville there The liver or in AH patient. the of in XX practice of scores population, of bilirubin reductions
the have who study. Lille Day X below DUR-XXX-treated X.XX. from hepatitis University were score Lille a study, score survival in Louisville of had X.XX compared rate trial, to of Patients That statistically X.XX scores significantly have historical a When visit, versus with of for the a of DUR-XXX XX%. XX% X.XX, Lille group the X-month the with alcoholic patients would score survival rate median X-month with those the who hepatitis for treated the about XX returned of In compares their was above XXX, the Lille median lower alcoholic the for patients Louisville patients scores. Lille the who only
or on just were a serious tolerated patients exposures with reported that DUR-XXX doses patients. Day DUR-XXX Louisville in compared had with of the bilirubin XX XX at all X or severity all and Lille, XX score XX% the level. in to XX% of or dose events discharged based at disease. the adverse dose XX patients X.XX was the the treated being below scheduled for After the Additionally, tested, no drug-related level Lille visits, and Drug as all and well return -- any study. did MELD reported I XX uninfluenced X of were therefore, Day Day data not follow-up X, on by one patient the proportional at
analysis follow-up not forward this We Dr. is with from did included XXXX. Study for on XX for McClain return patients will beginning the B. It number patients -- month. poster meeting that to XX the By period. at Association look follow-up of on one should the in that follow-up the the treated control this The poster X be Hall A Convention group in XX-day presented Disease noted, comparative trial the being data DUR-XXX Louisville however, for be later historic by contrast, presented for her that Hynes November Center, Liver died survived all its week. publication of Craig first XX visit, in at American Boston the data
oral by this Hynes in of November trial's given publication late-breaking one the the of be on Eastern auditorium XX Time Center Hassanein, main is And the a.m. LXX. number for will Tarek Our investigators. at presentation Dr. principal Convention X:XX the
Hassanein on a for presentation Dr. the answers that same present liver be Meeting will at the accessible Webex The and disease in the inclusion Liver also alcoholic-related his also will in be Eastern slide selected slide questions category. for available from website. noon study Best results on Webex were The Time will summary from this of our and day.
one and this from of disease. year's scientists Hassanein AH We Dr. and and who look the trial trial dedicated the therapeutic lack large largest acute among forward -- with to are which mortality McClain's of option. preventing Dr. liver is devastating, this gatherings These Meeting, is a Liver at and results presentations the to rates of a condition effective results professionals healthcare curing high for of of often increased and and recent typically and AH is study exciting we and hepatic year. of are a Phase help doses associated AH onset characterized of period start valuable the by us failure. recent select form intake to to long-term heavy next acute alcohol provide after IIb plan disease is occurs data consumption. alcoholic with alcohol an jaundice is liver of
in AH of with hospitalization United lead the States of hospitalizations a $XXX,XXX. $XX,XXX per XXX,XXX And transplant, or liver XXXX, over were in to patient. cost cases, which There exceeds in in resulting patients more the AH can some for cost
with oral and which In accepted level medical with Lille Positive in poster for summary, early data this this from bilirubin as of been reductions Data AH unmet week. presentation need DUR-XXX significant begins XX%. scores. meeting mortality as a have a of at low Boston, trial reduction the represents rates and shown and from has late-breaking MELD AASLD near-term serum patients clinical high dosed
has addition, was a to in IIb The Liver in In we placebo-controlled believe Meeting the the plan patients, be the Of abstract We slides. DUR-XXX trial included to Best AH and selected life-saving that start be next Phase to potential late-breaking year.
update DUR-XXX next The I'll the program. on program is NASH
point passed U.S. NASH have X Phase DUR-XXX The evaluating activity enrollment in study open-label pharmacokinetics in and biological a of with to Stage trial. fibrosis. clinical in halfway randomized, patients NASH the our X trial is Ib the We safety,
or for NASH we XXX once day. group will patients per days In with at twice day milligrams a milligrams this and are milligrams of XX dose consecutive approximately are a DUR-XXX are for orally XX patients These XX total be XX XXX at patients for XX taking patients approximately the a study, evaluable DUR-XXX in target of a trial. doses and evaluating least XX followed of per There afterwards days. group
well and include Key chemistry biomarkers by pharmacokinetics and content and endpoints clinical MRI-PDFF from fat study safety this liver as imaging. as
next of half We expect first year. complete trial to this in the
DUR-XXX the program. to Now psoriasis
enrollment psoriasis. is During the This a completed double-blind, daily After psoriasis on which plaque their one for DUR-XXX patients and followed vehicle-controlled, randomized, applied once the weeks plaque proof-of-concept treatment to trial trial. patients the for Phase DUR-XXX on applying similar weeks. period, additional an quarter, Each in the X a we IIa other own in in X patient with plaque moderate topically mild to control, is serves trial, our clinical to as arm vehicle up arm. are
plaques conducted evaluable of being Over is the with to have baseline the XX at that patients XX States. the goal endpoint DUR-XXX-treated The plaques. in vehicle-treated is the enrolled obtaining local primary as psoriasis multiple in scores change Trial United approximately from patients. of been efficacy sites in compared
data line the We of this year. expect this top announce trial to from end by
treatment Psoriasis the an to the million than is X.X And symptoms. population skin the days no irritation weeks. replace International or causes affects psoriasis. currently world's nearly have approved form and causes but according and skin cells about rather may painful. ease disease Americans. million some cure, Associations, There body to of in X% estimated itchiness of of an be Psoriasis that XXX people Federation Psoriasis inflammatory is Psoriasis can
have patients with of XX% psoriasis therapy. Approximately disease, which local treated topical with can be
mainstay agents of remain treatment. the As such, psoriasis topical
deal. we the access Gilead to for Gilead delivery during and commercialize option exclusive of that third where had the injectable business, hepatitis hepatitis most B. investigational platform received for directed the license and long-acting X had July, B recent and licensed our the to treatment product rights SABER announced a also B we In to HIV, drug being to SABER additional quarter, announcements and HIV utilizing our important exclusive the we Gilead develop Now SABER-based and products -- HIV technology. HIV hepatitis the to
milestone an potential and well Gilead a in as $XX with development an payment additional made $XX upfront as milestone million on additional of million, and product regulatory for million the tiered $XX sales-based sales. in an royalty
for of $XXX development, payment we hepatitis directed royalties program, the we an upfront earned million has in per tiered B September, milestone a option additional exclusive million October. In the license for milestones received Gilead and to as sales-based SABER-based this on to products in $XX payment regulatory which as and HIV first product under well sales. additional
products Gilead in B is a hepatitis to leader virus. and treat global HIV
year. In products patients sold in treating mission. fact, proud last HIV able are been treatment They years, many Gilead HIV $XX.X for directed billion and in to help them to this have to be we
SABER Our patented acetate technology for designed isobutyrate provide is technology, long-acting sucrose a product. to release is extended is which that injectable sustained release,
It that directly depot also deliver now designed POSIMIR. the administered the transition, bupivacaine move three up the days technology is our is surgery. site to investigational, to SABER pain SABER product technology. for an relief surgical As of into I'll reminder, be is POSIMIR a that basis With utilizes to after POSIMIR. postoperative to
the Simon meeting. FDA analgesic LLC, FDA's In is submission scientist -- XXXX POSIMIR a FDA tentatively for a for principal resubmission XXXX. the led January ophthalmologic our XXXX an leading Dr. and Committee research NDA our the -- Director FDG Dr. Simon, now submission. NDA FDA an who the until who Division July, file our agreed efforts from in now and meeting as firm. efforts to products Advisory preparation drug physician is prepare XX, to Committee has scheduled is Lee advisory and anti-inflammatory Advisory served The for direct
involving period all, well-controlled surgery adequate in meet safety company whom as a over X,XXX and hernia of POSIMIR and these surgery, pivotal X shoulder completed pain control POSIMIR safety trials decompression and We repair demonstrated patients in requirements has received have the in being postoperative consumed the conducted clinical to decrease sized is over believe the the compared program, a this in over and clinical XX-hour be POSIMIR In or trials patients, to in with reminder, clinical XX placebo. efficacy significant to considered following of inguinal trials opioids support a undergoing As the and database. trial. POSIMIR remainder the XXX subacromial and the patients. We pain sufficiently X- believe
the now additional PERSIST patients. submission new analyses sufficient that address The in safety current original included trial CRL. trial were the are that raised data there believe with and any as We not in FDA the data included, includes extensive included data concerns have such an the to NDA, XXX that PERSIST from FDA's that might the
there could setting, significant non-opioid No opportunity, the of today, pain indicating pain believe approved. that Regarding XX% approximately much new market the to experience it a are excuse severe postoperative if after contributor insufficient pain in an -- moderate remains important me, that postoperative and studies patients surgery. pain and needed with we control POSIMIR products is problem, be
space. we the hospital commercial license excellent in approved, a If with plan would partner POSIMIR to capabilities to
of value significant we could term. economic potential garner POSIMIR, deal the Given believe this
PERSERIS. today I'll product an is on provide update Final
end as agreement received injectable net earnout with of a we've our This quarterly part payment at February product long-acting with expect one representatives. a in force earnout of year so this the received Indivior, we've product And launch, of by so modest its for far. as early U.S. on of percentage based launched payment a As was a antipsychotic. single-digit of field sales Indivior, XX might reminder, PERSERIS,
from that is therapeutic revenue in to previously control option summary, to And $XXX reach Indivior In rate. with with expect mortality patients scores condition that high Phase quarter, they between may stated to group's that have have alcoholic most the expectations. life-saving compared revenue IIa data this peak million. the a compelling, the consistent announced good is drug be million the comparison they a net And controls, impressive. DUR-XXX trial annual data historic no historic for and to when suggests a are Lille $XXX
Tuesday oral Meeting XX forward -- look presentation We late-breaking Liver in poster on Boston. oral and the presentation on to the at the Sunday
were for inclusion presentation the We a Liver data for are Best that Meeting. late-breaking oral Of selected these and honored The in
investigators. encouragement from and support advisers are for clinical strong expert our the We thankful and
of commercial We is data to potential has The year. product DUR-XXX we're Com potential track Phase to first year. as The towards excited and proof-of-concept with and patients topical psoriasis IIa to top with glimpse the hepatitis the is We're XX-day the and directed completed of look enrollment SABER DUR-XXX forward products on half excited such do halfway HIV NASH condition be by getting to the on investigational look in prospect in than XXX all, B. what trial a a line the may HIV we have the enrolled, a of able hepatitis. completing this working January and well them be next injectable NDA as trial Ad the of in to end long-acting more to with of approval to as be devastating partnership. Most alcoholic additional and helping trial forward of POSIMIR Gilead
And might with to we'd any questions like that, you take now have.
